Efficacy and Safety of RC48 (Disitamab Vedotin) Combined With Sintilimab and SOX for HER2 IHC 1+/2+ Unresectable Locally Advanced or Advanced Gastric Cancer Conversion Therapy
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- R0 resection rate
研究概览
简要总结
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC 1+/2+ expression. The trial plans to enroll patients with a single initial unresectable factor and HER2 IHC 1+/2+ status. Participants will receive disitamab vedotin combined with sintilimab and SOX for 4 to 6 treatment cycles. Those who achieve successful conversion will undergo surgical resection, while patients with unsuccessful conversion will either continue the original regimen or switch to an alternative treatment at the investigator's discretion.
详细描述
This is an open-label, single-arm, exploratory study designed to enroll patients with a single initial unresectable factor and HER2 IHC 1+/2+ locally advanced or metastatic gastric cancer. The primary objective is to assess the efficacy of the combination regimen based on the R0 resection rate. Tumor response will be evaluated every 6 to 12 weeks via imaging to determine whether surgical criteria are met. Patients who meet the criteria for operability will proceed to surgery, and postoperative adjuvant therapy will be tailored by the investigator based on individual patient conditions. For those who do not achieve successful conversion, the investigator will decide whether to continue the original treatment or transition to an alternative therapeutic strategy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily enrolled and provided written informed consent;
- •Aged 18-70 years (inclusive), male or female;
- •Histologically and/or cytologically confirmed unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
- •No prior systemic anticancer therapy;
- •HER2 immunohistochemistry (IHC) result of 2+ or 1+, based on either previous test results (confirmed by the investigator) or central laboratory assessment;
- •Presence of a single initial unresectable factor;
- •At least one measurable lesion per RECIST 1.1;
- •Life expectancy ≥ 6 months;
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
- •Adequate organ function, defined as follows:
- •Hematological (within 14 days prior to screening, without transfusion or granulocyte colony-stimulating factor [G-CSF] support):
- •Hemoglobin ≥ 90 g/L;
- •Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
- •White blood cell count ≥ 3.0 × 10⁹/L;
- •Platelet count ≥ 80 × 10⁹/L;
- •Biochemical (within 14 days prior to screening, without albumin infusion):
- •Albumin ≥ 28 g/L;
- •Total bilirubin ≤ 2 × upper limit of normal (ULN);
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the absence of liver metastases; or ≤ 5 × ULN if liver metastases are present;
- •Serum creatinine ≤ 1.5 × ULN; or creatinine clearance (CrCl) ≥ 50 mL/min as calculated by the Cockcroft-Gault formula;
- •Coagulation:
- •International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
- •Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
排除标准
- •History of malignancies other than gastric cancer, with the following exceptions:
- •Malignancies treated with curative intent and with no evidence of disease for 5 years;
- •Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, or other in situ carcinomas.
- •Conditions affecting the absorption, distribution, metabolism, or excretion of the investigational drug(s) (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, malabsorption, etc.).
- •Previous allogeneic stem cell or solid organ transplantation.
- •Prior systemic antitumor therapy (including Chinese herbal medicine with antitumor indications) completed less than 4 weeks before the first dose of study treatment, or with prior treatment-related adverse events not recovered to ≤ CTCAE grade 1 (except for alopecia or pigmentation).
- •History or presence of congenital or acquired immunodeficiency disorders.
- •Active or previously documented autoimmune or inflammatory disorders (including but not limited to autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism, hypothyroidism, asthma requiring bronchodilators, etc.). Patients with vitiligo, childhood asthma that has fully resolved without intervention in adulthood, or other conditions deemed eligible by the investigator may be included.
- •Use of systemic immunosuppressive therapy within 2 weeks prior to enrollment, or anticipated need for such therapy during the study, with the following exceptions:
- •Intranasal, inhaled, topical, or local corticosteroid injections (e.g., intra-articular);
- •Systemic corticosteroids at a dose ≤ 10 mg/day prednisone or equivalent;
- •Prophylactic corticosteroids for hypersensitivity reactions.
- •Known or suspected history of hypersensitivity to disitamab vedotin, anti-PD-1 agents, chimeric or humanized antibodies or fusion proteins, or any excipient of the investigational drug(s).
- •History of thrombotic or thromboembolic events within the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc.
- •Patients assessed by the physician to be at significant risk of bleeding, including but not limited to:
- •Major bleeding (>30 mL within 3 months) or hemoptysis (>5 mL within 4 weeks); endoscopic evaluation may be performed to confirm eligibility;
- •Active bleeding or coagulation disorders;
- •Bleeding tendency or current use of thrombolytic, anticoagulant, or antiplatelet therapy.
研究组 & 干预措施
Conversion therapy
Drug: Disitamab Vedotin in combination with sintilimab and SOX
干预措施: Disitamab vedotin(RC48) (Drug)
Conversion therapy
Drug: Disitamab Vedotin in combination with sintilimab and SOX
干预措施: Sintilimab (Drug)
Conversion therapy
Drug: Disitamab Vedotin in combination with sintilimab and SOX
干预措施: S-1 (Drug)
Conversion therapy
Drug: Disitamab Vedotin in combination with sintilimab and SOX
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
R0 resection rate
时间窗: Within 1 month of surgery
Defined as no residue under the microscope after resection
次要结局
- Pathologic complete response(Within 1 month of surgery.)
- Overall survival(2 years from the start of system therapy.)
- 1/2-year survival rate(1/2 years from the start of system therapy.)
- Adverse events(all grades）(From the start of system therapy to 6 months after surgery.)
- Serious adverse events(≥grade 3）(From the start of system therapy to 6 months after surgery.)
研究者
Fenglin Liu
Director of Gastric Surgery
Fudan University